Cannara Biotech Statistics

Total Valuation

Cannara Biotech has a market cap or net worth of CAD 60.31 million. The enterprise value is 103.73 million.

Market Cap	60.31M
Enterprise Value	103.73M

Important Dates

The next estimated earnings date is Friday, November 29, 2024.

Earnings Date	Nov 29, 2024
Ex-Dividend Date	n/a

Share Statistics

Cannara Biotech has 90.02 million shares outstanding. The number of shares has increased by 2.09% in one year.

Current Share Class	n/a
Shares Outstanding	90.02M
Shares Change (YoY)	+2.09%
Shares Change (QoQ)	+1.67%
Owned by Insiders (%)	2.05%
Owned by Institutions (%)	n/a
Float	43.99M

Valuation Ratios

The trailing PE ratio is 11.37.

PE Ratio	11.37
Forward PE	n/a
PS Ratio	0.79
PB Ratio	0.74
P/TBV Ratio	n/a
P/FCF Ratio	52.28
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.15, with an EV/FCF ratio of 89.91.

EV / Earnings	19.51
EV / Sales	1.35
EV / EBITDA	7.15
EV / EBIT	12.06
EV / FCF	89.91

Financial Position

The company has a current ratio of 2.32, with a Debt / Equity ratio of 0.60.

Current Ratio	2.32
Quick Ratio	0.65
Debt / Equity	0.60
Debt / EBITDA	3.37
Debt / FCF	42.37
Interest Coverage	1.71

Financial Efficiency

Return on equity (ROE) is 6.78% and return on invested capital (ROIC) is 4.30%.

Return on Equity (ROE)	6.78%
Return on Assets (ROA)	3.78%
Return on Capital (ROIC)	4.30%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.54
Inventory Turnover	1.41

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.11% in the last 52 weeks. The beta is 1.08, so Cannara Biotech's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	-30.11%
50-Day Moving Average	0.65
200-Day Moving Average	0.75
Relative Strength Index (RSI)	50.48
Average Volume (20 Days)	32,288

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cannara Biotech had revenue of CAD 76.69 million and earned 5.32 million in profits. Earnings per share was 0.06.

Revenue	76.69M
Gross Profit	28.88M
Operating Income	8.60M
Pretax Income	5.32M
Net Income	5.32M
EBITDA	14.29M
EBIT	8.60M
Earnings Per Share (EPS)	0.06

Full Income Statement

Balance Sheet

The company has 5.46 million in cash and 48.88 million in debt, giving a net cash position of -43.42 million or -0.48 per share.

Cash & Cash Equivalents	5.46M
Total Debt	48.88M
Net Cash	-43.42M
Net Cash Per Share	-0.48
Equity (Book Value)	81.77M
Book Value Per Share	0.91
Working Capital	35.24M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 9.91 million and capital expenditures -8.76 million, giving a free cash flow of 1.15 million.

Operating Cash Flow	9.91M
Capital Expenditures	-8.76M
Free Cash Flow	1.15M
FCF Per Share	0.01

Full Cash Flow Statement

Margins

Gross margin is 37.65%, with operating and profit margins of 11.21% and 6.93%.

Gross Margin	37.65%
Operating Margin	11.21%
Pretax Margin	6.93%
Profit Margin	6.93%
EBITDA Margin	18.63%
EBIT Margin	11.21%
FCF Margin	1.50%

Dividends & Yields

Cannara Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.09%
Shareholder Yield	-2.09%
Earnings Yield	8.80%
FCF Yield	1.91%

Stock Splits

The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Feb 13, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Cannara Biotech has an Altman Z-Score of 1.56. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.56
Piotroski F-Score	n/a